1. 首頁 > 健康養生 > >

2022 IDWeeK美國感染性疾病周——新冠肺炎前沿速遞( 四 )

健康知識養生常識


2022 IDWeeK美國感染性疾病周——新冠肺炎前沿速遞
文章圖片
綜上 ， 2022年的IDWeek大會為我們帶來了新冠肺炎高危人群及新冠中和抗體等方面的最新研究進展 ， 這將給臨床專家帶來更多思考與見解 ， 為更好地保護高危人群 ， 治療新冠肺炎提供更多的科學的思路和方向 。
參考文獻
IDWeek大會官網：https://idweek.org/
1.http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml
2.288-PrognosticFactorsforIn-hospitalMortalityofPatientswithSevereCOVID-19HospitalizedintheUniversityMedicalCenter,Lithuania.
3.1086-COVID-19inacomprehensiveCancerCenter:2020-2022.
4.1089-Evaluationofbreakthroughinfectionsinsolidorgantransplantrecipients:theprospectiveCONTRASTcohort.
5.1939-COVID-19vaccineimmunogenicityamongCD19receptorT-cell(CAR-T)therapy.
6.LevinMJ,etal.NEnglJMed.2022Jun9;386(23):2188-2200.
7.MontgomeryH,etal.LancetRespirMed.2022Jun7;S2213-2600(22)00180-1
8.1160-Treatment-EmergentViralVariantsinthePhase3TACKLETrialInvestigatingEfficacyandSafetyofAZD7442(Tixagevimab/Cilgavimab)fortheTreatmentofMildtoModerateCOVID-19inAdults1066-Precisionphenotypingof“longCOVID”throughmachinelearning.
9.1110-AZD7442(Tixagevimab/Cilgavimab)DemonstratesPotentInVitroActivityAgainstSARS-CoV-2SpikeVariantsIdentifiedinCirculationandinProphylaxisClinicalStudies
10.1143-ProphylacticandTherapeuticActivityofAZD7442(Tixagevimab/Cilgavimab)inSARS-CoV-2HamsterChallengeModels
11.1918-ImpactoftheSARS-CoV-2–NeutralizingAntibodyCombinationAZD7442(Tixagevimab/Cilgavimab)ontheSeverityandProgressionofCOVID-19SymptomsinthePhase3TACKLETrial
12.1924-OutpatientTreatmentWiththeSARS-CoV-2–NeutralizingAntibodyCombinationAZD7442(Tixagevimab/Cilgavimab)forPreventingCOVID-19HospitalizationsinthePhase3TACKLETrial
13.1925-PrevalenceofSARS-CoV-2InfectioninImmunocompromisedPatientsFollowingReceiptofTixagevimab/Cilgavimab